BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22560714)

  • 21. Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients.
    St-Hilaire J; Sévigny C; Beaulieu F; Germain F; Lavoie C; Dagnault A; Gingras L; Tremblay D; Beaulieu L
    Radiother Oncol; 2009 Jun; 91(3):342-8. PubMed ID: 19135749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams.
    Luo W; Li J; Fourkal E; Fan J; Xu X; Chen Z; Jin L; Price R; Ma CM
    Phys Med Biol; 2008 Dec; 53(24):7151-66. PubMed ID: 19033641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy.
    Ding X; Li X; Zhang JM; Kabolizadeh P; Stevens C; Yan D
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1107-1116. PubMed ID: 27869083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosimetric feasibility of 4DCT-ventilation imaging guided proton therapy for locally advanced non-small-cell lung cancer.
    Huang Q; Jabbour SK; Xiao Z; Yue N; Wang X; Cao H; Kuang Y; Zhang Y; Nie K
    Radiat Oncol; 2018 Apr; 13(1):78. PubMed ID: 29695284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technical Note: 4D robust optimization in small spot intensity-modulated proton therapy (IMPT) for distal esophageal carcinoma.
    Feng H; Shan J; Ashman JB; Rule WG; Bhangoo RS; Yu NY; Chiang J; Fatyga M; Wong WW; Schild SE; Sio TT; Liu W
    Med Phys; 2021 Aug; 48(8):4636-4647. PubMed ID: 34058026
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Energy layer optimization strategies for intensity-modulated proton therapy of lung cancer patients.
    Jensen MF; Hoffmann L; Petersen JBB; Møller DS; Alber M
    Med Phys; 2018 Oct; 45(10):4355-4363. PubMed ID: 30129041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques.
    Verbakel WF; van Reij E; Ladenius-Lischer I; Cuijpers JP; Slotman BJ; Senan S
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e297-303. PubMed ID: 22579380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A treatment planning study of the potential of geometrical tracking for intensity modulated proton therapy of lung cancer.
    Munck af Rosenschöld P; Aznar MC; Nygaard DE; Persson GF; Korreman SS; Engelholm SA; Nyström H
    Acta Oncol; 2010 Oct; 49(7):1141-8. PubMed ID: 20831506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimated radiation pneumonitis risk after photon versus proton therapy alone or combined with chemotherapy for lung cancer.
    Vogelius IR; Westerly DC; Aznar MC; Cannon GM; Korreman SS; Mackie TR; Mehta MP; Bentzen SM
    Acta Oncol; 2011 Aug; 50(6):772-6. PubMed ID: 21767173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dose-volume histograms between proton beam and X-ray conformal radiotherapy for locally advanced non-small-cell lung cancer.
    Ohno T; Oshiro Y; Mizumoto M; Numajiri H; Ishikawa H; Okumura T; Terunuma T; Sakae T; Sakurai H
    J Radiat Res; 2015 Jan; 56(1):128-33. PubMed ID: 25368341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.
    Macdonald OK; Kruse JJ; Miller JM; Garces YI; Brown PD; Miller RC; Foote RL
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):950-8. PubMed ID: 19801106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dosimetric comparison of intensity-modulated proton therapy optimization techniques for pediatric craniopharyngiomas: a clinical case study.
    Yeung D; McKenzie C; Indelicato DJ
    Pediatr Blood Cancer; 2014 Jan; 61(1):89-94. PubMed ID: 24000229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer.
    Manon RR; Jaradat H; Patel R; Zhang T; Fenwick J; Tome W; Fowler J; Paliwal B; Soisson E; Yuan Z; Mehta M
    Clin Lung Cancer; 2005 Sep; 7(2):107-13. PubMed ID: 16179097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting.
    Kardar L; Li Y; Li X; Li H; Cao W; Chang JY; Liao L; Zhu RX; Sahoo N; Gillin M; Liao Z; Komaki R; Cox JD; Lim G; Zhang X
    Pract Radiat Oncol; 2014; 4(6):e259-68. PubMed ID: 25407877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uncertainty reduction in intensity modulated proton therapy by inverse Monte Carlo treatment planning.
    Morávek Z; Rickhey M; Hartmann M; Bogner L
    Phys Med Biol; 2009 Aug; 54(15):4803-19. PubMed ID: 19622848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of intensity-modulated radiation therapy as a boost treatment on the lung-dose distributions for non-small-cell lung cancer.
    Choi Y; Kim JK; Lee HS; Hur WJ; Chai GY; Kang KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):683-9. PubMed ID: 15927412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of robustness against setup uncertainties using probabilistic scenarios in lung cancer: a comparison of proton with photon therapy.
    Teoh S; George B; Fiorini F; Vallis KA; Van den Heuvel F
    Br J Radiol; 2020 Mar; 93(1107):20190584. PubMed ID: 31977241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study.
    Nichols RC; Huh SN; Henderson RH; Mendenhall NP; Flampouri S; Li Z; D'Agostino HJ; Cury JD; Pham DC; Hoppe BS
    Clin Lung Cancer; 2011 Jul; 12(4):252-7. PubMed ID: 21726825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy.
    Chi A; Lin LC; Wen S; Yan H; Hsi WC
    Radiat Oncol; 2017 Aug; 12(1):132. PubMed ID: 28810881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.